BiomX Inc.

# Signal Note: Deerfield Initiates BiomX Position Deerfield's $245K entry into PHGE suggests conviction in BiomX's phage therapy platform, likely ahead of clinical catalysts in chronic wound infections or other bacterial indications where phage therapeutics have shown clinical differentiation versus antibiotics. The position size is modest but notable given Deerfield's selective approach to healthcare multi-strategy investing, indicating the firm sees asymmetric risk-reward despite PHGE's current market cap pressures and competitive phage therapy landscape.